Patents by Inventor Margaret McCarrick

Margaret McCarrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230295178
    Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.
    Type: Application
    Filed: September 2, 2022
    Publication date: September 21, 2023
    Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
  • Publication number: 20230192698
    Abstract: The invention provides a chemical entity of Formula (I): , wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Application
    Filed: June 27, 2022
    Publication date: June 22, 2023
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Patent number: 11434247
    Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: September 6, 2022
    Assignee: Dart Neuroscience LLC
    Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
  • Patent number: 11186582
    Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: November 30, 2021
    Assignee: Dart Neuroscience, (Cayman) LTD.
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Publication number: 20200095256
    Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 26, 2020
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Patent number: 10501465
    Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 10, 2019
    Assignee: Dart Neuroscience (Cayman) Ltd.
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Publication number: 20180179216
    Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Application
    Filed: February 26, 2018
    Publication date: June 28, 2018
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Patent number: 9932345
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 3, 2018
    Assignee: Dart NeuroScience (Cayman) Ltd.
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Publication number: 20170057967
    Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
    Type: Application
    Filed: April 22, 2015
    Publication date: March 2, 2017
    Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
  • Publication number: 20080242694
    Abstract: Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.
    Type: Application
    Filed: September 17, 2007
    Publication date: October 2, 2008
    Inventors: Neil R. D'Sidocky, Roy L. Harris, Sayee G. Hegde, Robert Hilgraf, Margaret A. McCarrick, Jeffrey A. McKie, Deborah S. Mortensen, Lisa Nadolny, Sophie M. Perin-Ninkovic, John J. Sapienza, Jonathan L. Wright